Key Highlights

  • Third quarter net loss was USD 208.4 million, or USD 0.26 per share, against an estimated USD 0.28 loss.
  • Research and development expense was USD 169.1 million against USD 131.1 million, and general and administrative was USD 45.5 million.
  • AstraZeneca closed a USD 2.0 billion Equity Investment on October 5; cash stood at USD 150.8 million on September 30.
  • The FDA set a PDUFA goal action date of November 14, 2026 for the ivonescimab application in EGFR-mutated NSCLC.

What does a clinical-stage company report ahead of a November 14 FDA action date? Summit Therapeutics (NASDAQ:SMMT) posted a third quarter net loss of USD 208.4 million, or USD 0.26 per share, against an estimate of USD 0.28 loss per share and a loss of USD 0.31 a year earlier. The company reported no revenue, and its attention centered on the ivonescimab application and a new USD 2.0 billion equity investment.

The Ivonescimab Application and FDA Date

Summit submitted a Biologics License Application in the fourth quarter of 2025 for ivonescimab plus chemotherapy in EGFR-mutated, non-squamous NSCLC after a third-generation EGFR tyrosine kinase inhibitor. The FDA accepted it for filing in January 2026 and set a PDUFA goal action date of November 14, 2026. The agency noted that a statistically significant overall survival benefit is necessary to support Marketing authorization and that progression-free survival results from the study may not be sufficient.

In the HARMONi study, progression-free survival had a hazard ratio of 0.52, and median PFS was 6.8 months against 4.4 months. The primary overall survival hazard ratio was 0.79 (p=0.057), which did not reach statistical significance. An updated analysis with a June 2026 data cutoff showed an overall survival hazard ratio of 0.76 (nominal p=0.0151).

Pipeline Trials and Spending Lines

The HARMONi-3 trial compares ivonescimab plus chemotherapy with pembrolizumab plus chemotherapy in first-line metastatic NSCLC, with separate squamous and non-squamous analyses. The independent committee recommended that the squamous study continue as planned after an interim progression-free survival look. Management said the squamous event count for the primary analysis is projected in the fourth quarter of 2026 and the non-squamous count in the first half of 2027.

Research and development expense rose on clinical trial costs of USD 67.2 million against USD 38.7 million and Manufacturing and clinical material costs of USD 47.8 million against USD 30.8 million, tied to enrollment in HARMONi-3, HARMONi-7 and HARMONi-GI3. Stock-based compensation within general and administrative expense was USD 23.8 million against USD 90.2 million.

Capital Allocation and Balance Sheet

Cash and cash equivalents were USD 150.8 million and short-term investments were USD 479.0 million at September 30. Nine-month operating cash outflow was USD 423.2 million, and the net loss for nine months was USD 613.5 million. Financing inflows of USD 330.3 million came mainly from at-the-market share sales, and about USD 354.3 million remained available under the second distribution agreement.

On September 28 the company agreed to sell Class A convertible preferred stock to AstraZeneca, and the USD 2.0 billion closing took place on October 5. Conversion into 108,955,369 common shares at USD 18.3561 each depends on antitrust waiting-period expiry and stockholder approval, which stockholders granted on November 4. Management said cash, cash equivalents and short-term investments cover operating needs for at least 12 months.

Figures Worth Comparing

A quarterly net loss of USD 208.4 million sits alongside USD 150.8 million of cash, USD 479.0 million of short-term investments, a USD 2.0 billion investment received in October and a USD 2,907.7 million accumulated deficit.

Management named November 14, 2026 as the FDA action date, the fourth quarter of 2026 for the HARMONi-3 squamous event count and the first half of 2027 for the non-squamous count. It also noted new clinical trial collaborations with AstraZeneca, Daiichi Sankyo and Arcus, and stated that the AstraZeneca arrangements include no upfront or milestone payments.